MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
Authors Markowitz J, Abrams Z, Jacob N, Zhang X, Hassani J, Latchana N, Wei L, Regan K, Brooks T, Uppati S, Levine K, Bekaii-Saab T, Kendra K, Lesinski G, Howard J, Olencki T, Payne P, Carson III W
Received 13 February 2016
Accepted for publication 3 July 2016
Published 29 September 2016 Volume 2016:9 Pages 5931—5941
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Manfred Beleut
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Joseph Markowitz,1–4 Zachary Abrams,2,5 Naduparambil K Jacob,2,6 Xiaoli Zhang,2,7 John N Hassani,1 Nicholas Latchana,8 Lai Wei,2,7 Kelly E Regan,2,5 Taylor R Brooks,2 Sarvani R Uppati,2 Kala M Levine,2 Tanios Bekaii-Saab,2,4 Kari L Kendra,2,4 Gregory B Lesinski,2,4 J Harrison Howard,2,8 Thomas Olencki,2,4 Philip R Payne,2,5 William E Carson III2,8
1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, 2Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 3Department of Oncologic Sciences, USF Morsani School of Medicine, Tampa, FL, 4Division of Medical Oncology, The Ohio State University Wexner Medical Center, 5Department of Biomedical Informatics, 6Department of Radiation Oncology, 7Center for Biostatistics, 8Department of Surgery, The Ohio State University, Columbus, OH, USA
Background: MicroRNAs (miRNAs) are short noncoding RNAs that function to repress translation of mRNA transcripts and contribute to the development of cancer. We hypothesized that miRNA array-based technologies work best for miRNA profiling of patient-derived plasma samples when the techniques and patient populations are precisely defined.
Methods: Plasma samples were obtained from five sources: melanoma clinical trial of interferon and bortezomib (12), purchased normal donor plasma samples (four), gastrointestinal tumor bank (nine), melanoma tumor bank (ten), or aged-matched normal donors (eight) for the tumor bank samples. Plasma samples were purified for miRNAs and quantified using NanoString® arrays or by the company Exiqon. Standard biostatistical array approaches were utilized for data analysis and compared to a rank-based analytical approach.
Results: With the prospectively collected samples, fewer plasma samples demonstrated visible hemolysis due to increased attention to eliminating factors, such as increased pressure during phlebotomy, small gauge needles, and multiple punctures. Cancer patients enrolled in a melanoma clinical study exhibited the clearest pattern of miRNA expression as compared to normal donors in both the rank-based analytical method and standard biostatistical array approaches. For the patients from the tumor banks, fewer miRNAs (<5) were found to be differentially expressed and the false positive rate was relatively high.
Conclusion: In order to obtain consistent results for NanoString miRNA arrays, it is imperative that patient cohorts have similar clinical characteristics with a uniform sample preparation procedure. A clinical workflow has been optimized to collect patient samples to study plasma miRNAs.
Keywords: miRNA, profiling, melanoma, rank-based statistic
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]